{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T20:26:26Z","timestamp":1766003186308,"version":"3.48.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T00:00:00Z","timestamp":1760054400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002973","name":"Daiichi-Sankyo","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002973","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002336","name":"Daiichi Sankyo Co Ltd","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002336","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jacc.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JACC: Advances"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jacadv.2025.102329","type":"journal-article","created":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T23:49:20Z","timestamp":1763596160000},"page":"102329","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"P1","title":["Edoxaban Dose Adjustment and Age-Associated Outcomes in Patients With Atrial Fibrillation Post-Transcatheter Aortic Valve Replacement"],"prefix":"10.1016","volume":"4","author":[{"given":"Nicolas M.","family":"Van Mieghem","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Cathy","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian","family":"Hengstenberg","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Van Zyl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuya","family":"Kimura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0485-2692","authenticated-orcid":false,"given":"Irene","family":"Lang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5546-262X","authenticated-orcid":false,"given":"Roxana","family":"Mehran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johny","family":"Nicolas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Unverdorben","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.L.","family":"Zamorano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"George D.","family":"Dangas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jacadv.2025.102329_bib1","first-page":"524","article-title":"2021 ESC\/EACTS guidelines for the management of valvular heart disease: developed by the task force for the management of valvular heart disease of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)","volume":"75","author":"Vahanian","year":"2022","journal-title":"Rev Esp Cardiol (Engl Ed)"},{"key":"10.1016\/j.jacadv.2025.102329_bib2","doi-asserted-by":"crossref","first-page":"e25","DOI":"10.1016\/j.jacc.2020.11.018","article-title":"2020 ACC\/AHA guideline for the management of patients with valvular heart disease: a report of the American College of Cardiology\/American Heart Association joint committee on clinical practice guidelines","volume":"77","author":"Otto","year":"2021","journal-title":"J Am Coll Cardiol"},{"issue":"17","key":"10.1016\/j.jacadv.2025.102329_bib3","first-page":"1285","article-title":"Atrial fibrillation in patients undergoing transcatheter aortic valve implantation: epidemiology, timing, predictors, and outcome","volume":"38","author":"Tarantini","year":"2017","journal-title":"Eur Heart J"},{"issue":"9","key":"10.1016\/j.jacadv.2025.102329_bib4","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1016\/j.jcin.2016.01.037","article-title":"Prevalence and impact of atrial fibrillation in patients with severe aortic stenosis undergoing transcatheter aortic valve replacement: an analysis from the SOURCE XT prospective multicenter registry","volume":"9","author":"Tarantini","year":"2016","journal-title":"JACC Cardiovasc Interv"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102329_bib5","first-page":"279","article-title":"Safety of switching from a vitamin K antagonist to a non-vitamin K antagonist oral anticoagulant in frail older patients with atrial fibrillation: results of the FRAIL-AF randomized controlled trial","volume":"149","author":"Joosten","year":"2024","journal-title":"Circulation"},{"issue":"12","key":"10.1016\/j.jacadv.2025.102329_bib6","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1016\/j.jacc.2020.07.045","article-title":"Mortality in patients with atrial fibrillation receiving nonrecommended doses of direct oral anticoagulants","volume":"76","author":"Camm","year":"2020","journal-title":"J Am Coll Cardiol"},{"issue":"24","key":"10.1016\/j.jacadv.2025.102329_bib7","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1016\/j.jacc.2016.09.966","article-title":"Off-label dosing of non-vitamin K antagonist oral anticoagulants and adverse outcomes: the ORBIT-AF II registry","volume":"68","author":"Steinberg","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102329_bib8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2165\/11319540-000000000-00000","article-title":"Reasons for undertreatment with oral anticoagulants in frail geriatric outpatients with atrial fibrillation: a prospective, descriptive study","volume":"27","author":"Tulner","year":"2010","journal-title":"Drugs Aging"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102329_bib9","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40119-013-0019-y","article-title":"Anticoagulation in patients aged \u226575 years with atrial fibrillation: role of novel oral anticoagulants","volume":"2","author":"Ng","year":"2013","journal-title":"Cardiol Ther"},{"issue":"23","key":"10.1016\/j.jacadv.2025.102329_bib10","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1056\/NEJMoa2111016","article-title":"Edoxaban versus vitamin K antagonist for atrial fibrillation after TAVR","volume":"385","author":"Van Mieghem","year":"2021","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jacadv.2025.102329_bib11","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.003432","article-title":"Efficacy and safety of edoxaban in elderly patients with atrial fibrillation in the ENGAGE AF-TIMI 48 trial","volume":"5","author":"Kato","year":"2016","journal-title":"J Am Heart Assoc"},{"issue":"21","key":"10.1016\/j.jacadv.2025.102329_bib12","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.122.029865","article-title":"Benefits and harms of standard versus reduced-dose direct oral anticoagulant therapy for older adults with multiple morbidities and atrial fibrillation","volume":"12","author":"Hayes","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacadv.2025.102329_bib13","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ahj.2018.07.006","article-title":"Edoxaban versus standard of care and their effects on clinical outcomes in patients having undergone transcatheter aortic valve implantation in atrial fibrillation-rationale and design of the ENVISAGE-TAVI AF trial","volume":"205","author":"Van Mieghem","year":"2018","journal-title":"Am Heart J"},{"issue":"1","key":"10.1016\/j.jacadv.2025.102329_bib14","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/ki.2014.195","article-title":"Morbidity and treatment in patients with atrial fibrillation and chronic kidney disease","volume":"87","author":"Reinecke","year":"2015","journal-title":"Kidney Int"},{"issue":"6","key":"10.1016\/j.jacadv.2025.102329_bib15","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13745","article-title":"Impact of renal impairment on atrial fibrillation: ESC-EHRA EORP-AF long-term general registry","volume":"52","author":"Ding","year":"2022","journal-title":"Eur J Clin Invest"},{"issue":"8","key":"10.1016\/j.jacadv.2025.102329_bib16","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1016\/j.amjmed.2016.02.028","article-title":"Mortality in patients with atrial fibrillation randomized to edoxaban or warfarin: insights from the ENGAGE AF-TIMI 48 trial","volume":"129","author":"Giugliano","year":"2016","journal-title":"Am J Med"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102329_bib17","doi-asserted-by":"crossref","first-page":"52","DOI":"10.31083\/j.rcm2502052","article-title":"All-cause death and major adverse events in atrial fibrillation with frailty: observations from the Korea national health insurance service data","volume":"25","author":"Park","year":"2024","journal-title":"Rev Cardiovasc Med"},{"issue":"4","key":"10.1016\/j.jacadv.2025.102329_bib18","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1007\/s40256-023-00582-9","article-title":"Management of gastrointestinal bleeding and resumption of oral anticoagulant therapy in patients with atrial fibrillation: a multidisciplinary discussion","volume":"23","author":"Martin","year":"2023","journal-title":"Am J Cardiovasc Drugs"},{"issue":"48","key":"10.1016\/j.jacadv.2025.102329_bib19","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031953","article-title":"Gastrointestinal bleeding during the transcatheter aortic valve replacement perioperative period: a review","volume":"101","author":"Lu","year":"2022","journal-title":"Medicine (Baltimore)"},{"issue":"9984","key":"10.1016\/j.jacadv.2025.102329_bib20","doi-asserted-by":"crossref","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","article-title":"Association between edoxaban dose, concentration, anti-factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial","volume":"385","author":"Ruff","year":"2015","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.jacadv.2025.102329_bib21","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","article-title":"Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial","volume":"9","author":"Zimerman","year":"2024","journal-title":"JAMA Cardiol"},{"issue":"2","key":"10.1016\/j.jacadv.2025.102329_bib22","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1056\/NEJMoa1911425","article-title":"A controlled trial of rivaroxaban after transcatheter aortic-valve replacement","volume":"382","author":"Dangas","year":"2020","journal-title":"N Engl J Med"},{"issue":"22","key":"10.1016\/j.jacadv.2025.102329_bib23","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","article-title":"Edoxaban versus warfarin in patients with atrial fibrillation","volume":"369","author":"Giugliano","year":"2013","journal-title":"N Engl J Med"}],"container-title":["JACC: Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007586?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2772963X25007586?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T20:23:19Z","timestamp":1766002999000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2772963X25007586"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2772963X25007586"],"URL":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102329","relation":{},"ISSN":["2772-963X"],"issn-type":[{"type":"print","value":"2772-963X"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Edoxaban Dose Adjustment and Age-Associated Outcomes in Patients With Atrial Fibrillation Post-Transcatheter Aortic Valve Replacement","name":"articletitle","label":"Article Title"},{"value":"JACC: Advances","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacadv.2025.102329","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier on behalf of the American College of Cardiology Foundation.","name":"copyright","label":"Copyright"}],"article-number":"102329"}}